Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria

Autor: Michael Kossmeier, Madeleine Themanns, Lena Hatapoglu, Bernhard Kogler, Simon Keuerleber, Jutta Lichtenecker, Robert Sauermann, Anna Bucsics, Michael Freissmuth, Eva Zebedin-Brandl

Publikováno v: Frontiers in Pharmacology, Vol 12 (2021)

Objectives: Reimbursement decisions on new medicines require an assessment of their value. In Austria, when applying for reimbursement of new medicines, pharmaceutical companies are also obliged to submit forecasts of future sales. We systematically

Externí odkaz: https://doaj.org/article/8b960d61b34a44da9e9395de9677eee2

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

Autor: Patricia Vella Bonanno, Michael Ermisch, Brian Godman, Antony P. Martin, Jesper Van Den Bergh, Liudmila Bezmelnitsyna, Anna Bucsics, Francis Arickx, Alexander Bybau, Tomasz Bochenek, Marc van de Casteele, Eduardo Diogene, Irene Eriksson, Jurij Fürst, Mohamed Gad, Ieva Greičiūtė-Kuprijanov, Martin van der Graaff, Jolanta Gulbinovic, Jan Jones, Roberta Joppi, Marija Kalaba, Ott Laius, Irene Langner, Ileana Mardare, Vanda Markovic-Pekovic, Einar Magnusson, Oyvind Melien, Dmitry O. Meshkov, Guenka I. Petrova, Gisbert Selke, Catherine Sermet, Steven Simoens, Ad Schuurman, Ricardo Ramos, Jorge Rodrigues, Corinne Zara, Eva Zebedin-Brandl, Alan Haycox

Publikováno v: Frontiers in Pharmacology, Vol 8 (2017)

Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The “introduction” of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompl

Externí odkaz: https://doaj.org/article/f04463fb5300454ea10bcc289ffc51ff

Regimen-dependent synergism and antagonism of treprostinil and vildagliptin in hematopoietic cell transplantation

Autor: Michaela Prchal-Murphy, Elizabeth Heyes, Madeleine Themanns, Shahrooz Nasrollahi-Shirazi, Zahra Kazemi, Katrin Meissl, Wolfgang Strohmaier, Eva Zebedin-Brandl, Michael Freissmuth, Guenther Krumpl, Marion Mussbacher

Publikováno v: Journal of Molecular Medicine (Berlin, Germany)

Abstract The cell dose in umbilical cord blood units is a major determinant for the outcome of hematopoietic cell transplantation. Prostaglandin analogs and dipeptidylpeptidase-4 (DPP4/CD26)-inhibitors enhance the ability of hematopoietic stem cells

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f868343ed0888001d20fea2c7844905
https://doi.org/10.1007/s00109-019-01869-8

Treprostinil reduces endothelial damage in murine sinusoidal obstruction syndrome

Autor: Eva Zebedin-Brandl, Christian Bergmayr, Wolfgang Strohmaier, Alicja Chrzan, Madeleine Themanns, Michael Freissmuth, Johannes Haybaeck, Florian Koban

Publikováno v: Journal of Molecular Medicine (Berlin, Germany)

Sinusoidal obstruction syndrome (SOS) is a major complication after hematopoietic stem cell transplantation and belongs to a group of diseases increasingly identified as transplant-related systemic endothelial disease. Administration of defibrotide a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8827c57e285ff5109d8f4a568ebd4b0b
https://doi.org/10.1007/s00109-018-1726-6

Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice

Autor: Xiaonan Han, Nicole Golob-Schwarzl, Richard Moriggl, Wolfgang Mikulits, Markus H. Heim, Sonja M. Kessler, Doris Kaltenecker, Kristina M. Mueller, Katrin Friedbichler, Johannes Haybaeck, Jamile Paier-Pourani, Eva Zebedin-Brandl, Doris Schneller, Thomas Mohr, Lukas Kenner, Kay Uwe Wagner, Andrey V. Kozlov, Michaela Schlederer, Fabrice Gouilleux, Luigi Terracciano, Madeleine Themanns, Jérôme Bourgeais

Publikováno v: Scientific Reports
Scientific Reports, Nature Publishing Group, 2016, 6 (1), ⟨10.1038/srep34719⟩
Scientific Reports, 2016, 6 (1), ⟨10.1038/srep34719⟩

Genetic deletion of the tyrosine kinase JAK2 or the downstream transcription factor STAT5 in liver impairs growth hormone (GH) signalling and thereby promotes fatty liver disease. Hepatic STAT5 deficiency accelerates liver tumourigenesis in presence

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42c984f8a193c46649befec39a09d8f5
https://hal-univ-tours.archives-ouvertes.fr/hal-02411728